Somatostatin is the regulatory peptide hormone whose receptors, especially somatostatin receptor 2 (SSTR2), anchor much of neuroendocrine tumor medicine. Synthetic analogs such as octreotide and lanreotide control hormone-secreting tumors, and the same SSTR2 target guides peptide radioligands to cancer cells for both imaging and therapy.
That dual use runs through recent coverage. Novartis's Lutathera (lutetium-177 dotatate) delivers radiation to SSTR2-positive tumors, ITM's Lu-edotreotide sits in late-stage review, and Lantheus's gallium-68 edotreotide is a diagnostic imaging kit that maps where those receptors are expressed. Lantheus drew an FDA complete response letter on June 26, 2026 tied to a third-party manufacturer rather than any clinical shortfall, a reminder of how tightly the somatostatin-targeted category depends on radiopharmaceutical supply chains.
Stories here cover somatostatin analogs, SSTR2-directed radioligands, and the imaging tools that pair with them. See #neuroendocrine-tumors, #prrt, #radiopharmaceutical, and #lantheus.
On June 26, Lantheus disclosed a complete response letter for LNTH-2501, its gallium-68 edotreotide PET diagnostic kit for locating somatostatin-receptor-positive neuroendocrine tumors in adults and children. The FDA cited unresolved inspection conditions at the third-party facility that manufactures the drug product and could not approve by the June 29 PDUFA date. The agency raised no concerns about the clinical data, safety, or efficacy. CEO Mary Anne Heino said the feedback 'relates solely to our third-party manufacturer, and not to the clinical performance of the product.'
Camurus's resubmitted NDA for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target action date of June 10. The resubmission, accepted in January 2026 after a Complete Response Letter tied solely to a third-party manufacturing inspection, rests on data from seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would put Oclaiz alongside Crinetics' Palsonify (paltusotine) as the second new-mechanism acromegaly therapy in the past year, with the Camurus FluidCrystal differentiation focused on a small-volume monthly self-injection.
Camurus' Oclaiz (CAM2029), a once-monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target date of June 10 for acromegaly. The resubmitted NDA, accepted after a Complete Response Letter tied to a third-party manufacturing inspection, rests on seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would add a peptide depot to the somatostatin-analog market alongside Crinetics' newly launched oral Palsonify.
Crinetics Pharmaceuticals announced April 27 that the European Commission approved Palsonify (paltusotine), a selectively-targeted somatostatin receptor type 2 nonpeptide agonist, as the first once-daily oral therapy for acromegaly in adults across all 27 EU member states plus three EEA countries. The approval rests on two pivotal Phase 3 trials in medical-naïve and previously treated patients, with diarrhea, abdominal pain, and nausea reported as the most common adverse reactions and no serious adverse events in the randomized portion. First launches are planned for Germany and Austria, marking Crinetics' first regulatory approval outside the U.S. and a competitive challenge to injectable somatostatin analogs.